EN DE
Watch PRECIGEN, INC. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

PRECIGEN, INC. (PGEN) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of PRECIGEN, INC. stock $2.57, price $4.52, that is 43.1% below the price, quality 21 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PI PRECIGEN, INC. logo Thin data Nov 10, 2026

PRECIGEN, INC.

PGEN · US
Very expensive, weak quality

Our calculation puts a fair price 43% below what the stock costs today.

Upbeat coverage
Revenue last quarter +63% vs. a year ago.
Insiders bought $24,662 (6M) · sold $8.0M
Fair value $2.57 · Strongly overvalued
Quality 21/100
Weak Growth (revenue 5y −21.3 %/yr in USD)
Loss-making · -184.0% net margin (TTM)
High debt
Negative free cash flow
Trails peers (2/8)
Narrow moat 37/100
Thin data
Estimate
Watch PRECIGEN, INC. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$8.56 $0.6700 Fair Value $2.57 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.6700 – $8.56 · fair‑value band $1.93 – $3.22 · the $4.52 price screens above the $2.57 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow PRECIGEN in your weekly email

Every Wednesday you see whether PRECIGEN is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.

Show moreShow less

The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.

It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors.

In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis.

Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Stock analysis

PRECIGEN, INC. (PGEN) currently trades at $4.52, while our estimate is $2.57, 43% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.93 (bear) to $3.22 (bull), the price of $4.52 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

PRECIGEN, INC. reported revenue of $9.7M in FY2025 versus $14.3M in FY2021, a compound −9.2%/yr. Reported net income was −$251M in FY2025.

Key figures

Market cap $1.9B Small · P/S ratio 17.6 · EPS (TTM) $−0.8700 · Return on equity −837% · Return on assets (EBIT) −57.5% (5-year average) · Operating margin 41.2% · Revenue growth (YoY) +63.2% · Free cash flow −$89.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (medium confidence).

What moves the price

The share trades about 47% below its 52-week high and 46% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −43%, PGEN screens richer than that median.

Fair Value

Bear $1.93 Fair Value $2.57 Bull $3.22
Price $4.52 · Downside -43.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 21/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 74
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 18
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 32
How calm the share price moves, does not count
Price momentum 52
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 39
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $24,662, on Aug 21, 2026. Over the same period, 6 people sold shares worth $8.0M.

  • SaleJeffrey B KindlerDirector2× since Dec 12, 2025: 420,467 shares, avg. $5.31$2.2MAug 26, 2026
  • SalePhil TennantChief Commercial Officer2× since May 28, 2026: 109,438 shares, avg. $6.63$725,731Aug 25, 2026
  • SaleRutul R ShahChief Operating Officer5× since May 28, 2026: 202,138 shares, avg. $6.22$1.3MAug 25, 2026
  • BuyNancy H AgeeDirector3,411 shares at $7.23$24,662Aug 21, 2026
  • SaleHarry Thomasian Jr.Chief Financial Officer3× since May 28, 2026: 341,884 shares, avg. $5.56$1.9MJul 31, 2026
  • SaleHelen SabzevariPresident and CEO2× since May 28, 2026: 466,086 shares, avg. $5.50$2.6MJun 29, 2026
  • SaleDonald P. LehrChief Legal Officer29,131 shares at $4.36$127,011May 28, 2026
  • SaleRandal J KirkDirector, 10% owner3× since Nov 19, 2025: 9,639,110 shares, avg. $3.73$36.0MMar 30, 2026

Plus 14 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+146.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−28.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−21.3%
Start year 2020 (pandemic). Over 10 years: −25.1% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−269.8% (2020) → −1,100.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PGEN screens overvalued: fair value 43% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Recent news

News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare PRECIGEN, INC. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 21 · Bottom 25%
Fair Value upside −43.1% · Bottom 25%
Profitability
Return on assets −160.0% · Bottom 25%
Net margin (12 months) −184.0% · Bottom 25%
Operating margin (12 months) 41.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 63.2% · Top 25%
Balance sheet
Debt / equity 4.46× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (12 months) 21.81× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs PGEN
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs PGEN
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs PGEN
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs PGEN
argenx SE ARGX $971.55 $908.40 −7% vs PGEN
CSL Limited CSL A$201.68 A$181.40 −10% vs PGEN
Moderna, Inc MRNA $250.83 $158.70 −37% vs PGEN
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs PGEN
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs PGEN
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs PGEN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PRECIGEN, INC.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "PRECIGEN, INC. Fair Value". https://www.fairvalue-calculator.com/stock/PGEN

Frequently asked questions

Is PRECIGEN, INC. (PGEN) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $2.57 versus a price of $4.52, about 43% lower (overvalued).
What is the fair value of PGEN?
Our estimate for PRECIGEN, INC. is $2.57 (as of Nov 10, 2026), built from audited fundamentals. The current price: $4.52.
What is the quality score of PGEN?
PRECIGEN, INC. has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PRECIGEN, INC. (PGEN)?
Our calculated price target is the estimate of $2.57 (as of Nov 10, 2026). Cautious scenario $1.93, optimistic scenario $3.22. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the PRECIGEN, INC. stock forecast for 2026?
Our estimate puts fair value at $2.57, about 43% lower versus a price of $4.52 (overvalued). Cautious scenario $1.93, optimistic scenario $3.22. The calculation is refreshed regularly with new filings.
What is the intrinsic value of PRECIGEN, INC. (PGEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PRECIGEN, INC. it is $2.57 per share (as of Nov 10, 2026), against a price of $4.52.
Is PRECIGEN, INC. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PGEN trades above its calculated fair value: price $4.52, fair value $2.57, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PGEN?
No. The price is what the market pays today ($4.52); the fair value is what the company's own numbers justify ($2.57). For PRECIGEN, INC. the two are $1.95 per share apart. That gap is exactly why we show both numbers side by side.
How much is PRECIGEN, INC. worth?
The market values PRECIGEN, INC. at about $1.9B (market capitalisation, as of Nov 10, 2026). Per share that is $4.52; our models calculate a fair value of $2.57 per share.
What do the bullish and bearish scenarios say about PGEN?
Our models span a range for PRECIGEN, INC.: cautious scenario $1.93, base $2.57, optimistic $3.22 per share (as of Nov 10, 2026, price $4.52). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PRECIGEN, INC. (PGEN)?
Balance-sheet figures for PRECIGEN, INC. (as of Nov 10, 2026): debt of 4.46 per unit of equity. They feed the Quality Score of 21/100, which measures business quality independently of the share price.
How far is PGEN from its 52-week high?
PRECIGEN, INC. trades at $4.52, about 47% below its 52-week high of $8.56 and 46% above the low of $3.10 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $2.57 is for.
Which stocks are comparable to PRECIGEN, INC.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PRECIGEN, INC. stock attractive at the current price?
The data as of Nov 10, 2026: price $4.52, calculated fair value $2.57 (−43%), Quality Score 21/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. PRECIGEN, INC. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PRECIGEN, INC. (PGEN)?
The closing price on Nov 10, 2026 was $4.52. Our estimate is $2.57, about 43% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PRECIGEN, INC. right now?
The price sits above even our optimistic bull case ($3.22). The favourable scenario is already priced in. Weak quality (21/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of PRECIGEN, INC.

How large is the market capitalisation of PRECIGEN, INC. (PGEN)?
The market capitalisation of PRECIGEN, INC. is $1.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PRECIGEN, INC. (PGEN)?
The price-to-sales ratio of PRECIGEN, INC. is 17.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PRECIGEN, INC. (PGEN)?
Earnings per share at PRECIGEN, INC. are $−0.8700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of PRECIGEN, INC. (PGEN)?
The return on equity (ROE) of PRECIGEN, INC. is −837% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PRECIGEN, INC. (PGEN)?
On an EBIT basis the return on assets of PRECIGEN, INC. is −57.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PRECIGEN, INC. (PGEN)?
The operating margin of PRECIGEN, INC. is 41.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PRECIGEN, INC. (PGEN)?
Revenue at PRECIGEN, INC. is growing +63.2% versus a year earlier (3y avg −28.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does PRECIGEN, INC. (PGEN) generate?
The free cash flow of PRECIGEN, INC. is −$89.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does PRECIGEN, INC. (PGEN) carry?
The net debt of PRECIGEN, INC. is $68.1M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch PRECIGEN, INC. in the live analysis

One click puts PRECIGEN, INC. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.